Truqap (Capivasertib) Patent Expiration, LOE Window & CMS Spending

Truqap (Capivasertib) by AstraZeneca: FDA Orange Book core substance LOE 2033-04-16, 0 AB generics, $214.6M 2024 CMS Part D & Medicaid spend, and $22,922 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstraZeneca
FDA Application & PathwayN218197 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2033-04-16
Last Listed Patent or Exclusivity Date2033-04-16
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$214.6M
2024 Medicare Part D Spend$184.2M
2024 Medicaid Spend$30.4M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($22,922 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.